Purpose We report a retrospective comparison between bi-dimensional RANO criteria and manual volumetric segmentation (MVS) in pediatric low-grade gliomas. Methods MRI FLAIR or T1 post contrast images were used for assessment of tumor response. Seventy patients were included in this single center study, for each patient two scans were assessed (Btime 0^and Bend of therapy^) and response to therapy was evaluated for both methods. Inter-reader variability and average time for volumetric assessment were also calculated. Results Fourteen (20%) of the 70 patients had discordant results in terms of response assessment between the bi-dimensional measurements and MVS. All volumetric response assessments were in keeping with the subjective analysis of tumor (radiology report). Of the 14 patients, 6 had stable disease (SD) on MVS and progressive disease (PD) on 2D assessment, 5 patients had SD on MVS and partial response (PR) on 2D assessment, 2 patients had PD on MVS and SD on 2D assessment, and 1 patient had PR on MVS and SD on 2D analysis. The number of discordant results rises to 21(30%) if minor response is integrated in the response assessment. MVS was relatively fast and showed high inter-reader concordance. Conclusion Our analysis shows that therapeutic response classification may change in a significant number of children by performing a volumetric tumor assessment. Furthermore, MVS is not particularly time consuming and has very good inter-reader concordance.
Introduction
Pediatric low-grade gliomas (pLGGs) are a heterogeneous category of neoplasms, consisting most commonly of pilocytic astrocytomas with a favorable 5-year survival rate, but with a potential for recurrence, particularly in those incompletely resected [1, 2] . Although some pLGGs in accessible locations, such as the cerebellum, may be surgically cured, a large number of children will require adjuvant treatment.
Over the last decades, chemotherapy has been increasingly used in the management of unresectable and/or progressive pLGGs, particularly in young children [3] . It has therefore become essential to titrate adjuvant therapies carefully to tumor response. Together with the patient's clinical condition, imaging assessment forms the principal criterion by which pLGG treatment efficacy is measured, whereby one of the major challenges is response quantification. Currently there is no widely validated method for pediatric brain tumor response assessment [4] .
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The Macdonald criteria were first published in 1990 as guidelines for response assessments in adult supratentorial malignant gliomas, using the product of perpendicular measurements of enhancing tumor on axial post-contrast images as a measure of tumor burden [5] . To incorporate non-enhancing tumor changes into the response assessment, and to address the problem of Bpseudoprogression,^the RANO criteria were subsequently published in 2010 [6] . Despite some gain in assessment accuracy compared to previous methods, there are major limitations to the RANO criteria [7] and there is neither evidence nor consensus for the usefulness of these criteria in pLGGs.
First of all, enhancement of pLGGs is variable, heterogeneous, and not representative of the tumor grade [8] . Additionally, there is no clear consensus that an objective response translates to improvements in progression-free survival [4] , with some authors reporting good correlation between response and progression-free survival [9] , and others not [10] . Pediatric brain tumors as a whole, and pLGGs in particular, differ significantly in prognosis and clinical course compared to their adult counterparts. The extrapolation of parameters of assessment for adult malignant gliomas has not been validated in the pediatric setting and it is probably suboptimal [11] .
pLGGs are non-spherical and often have complex, mixed solid, and cystic components. Some irregularly shaped neoplasms such as visual pathway and hypothalamic gliomas may not be amenable to surgery but have a significant risk of progression. In view of this, accurate imaging assessment in this group of patients is particularly important and this is why RANO assessment criteria for pLGGs have included minor response criteria to include tumors which show a 25-49% reduction in the area of non-enhancing lesion on T2/FLAIR [12] .
Several studies have evaluated the role of one-dimensional, two-dimensional, and volumetric assessment of size in brain tumors [13, 14] . These studies have largely focused on adult cohorts of patients, and include two pediatric comparative studies: the first by Warren et al., of one-, two-and threedimensional measurements of childhood high grade brain tumors [15] , and the second by Kilday et al. on a small cohort (n = 8) of pLGGs [16] .
The aim of this study was to perform a comparison between bi-dimensional measurements of tumor diameter based on the RANO method and manual volumetric segmentations (MVS) for pLGGs to determine response assessment. Furthermore, we evaluated the clinical feasibility of manual volumetry in terms of time-consuming and inter-reader concordance.
Methods

Study population
Patients with LGG treated with weekly vinblastine at Sickkids (SK) hospital were included in this study. Some of the patients were from a phase II Canadian trial [17] ; the rest were treated as SK policies. Patients were included in the study if there was consensus between the two neuroradiologists (SL and FD'A, with, respectively, 25 and 3 years of experiences as pediatric neuroradiologists) that there was evidence of clearly measurable disease. Six patients with neurofibromatosis type 1 (NF1) were excluded since a clear distinction between tumor and NF1-related foci of abnormal signal intensity (FASI) was difficult at the level of the basal ganglia.
All patients underwent MR imaging assessment at several time points (weeks 26, 39, 52, and 70). For each patient, two scans were analyzed: time point Bzero^is defined as the baseline scan (within 4 weeks prior to the initiation of vinblastine), and follow-up examination at the end of therapy (average 522 days). Each subject was assigned to one of the categories Bprogressive disease (PD),^Bstable disease (SD),^or Btumor partial response (PR)^using data available in literature for each of the 2D and volumetric assessments. Patients were considered eligible for analysis if their tumor measured at least 10 × 10 mm in maximum perpendicular diameter (definition of measurable lesion according to RANO criteria) and if the tumor could be visualized on a minimum of four consecutive slices. Tumors within the spinal cord, and patients with evidence of metastatic disease were excluded from the analysis.
Image acquisition
The MR images used for tumor assessment were FLAIR images, with the exception of those patients, in whom complete enhancement was present on the T1 post contrast sequences on both the scans. All images were acquired on either 1. 
Data analysis
The margins of tumor and ideal sequences to identify the tumor margins were established by consensus between the two neuroradiologists. The majority of tumors showed variable enhancement, and delineation of tumor borders was best achieved in T2 FLAIR in 72% of patients. However, for completely enhancing tumors, for example chiasmatic optic pathway gliomas, the T1 post-contrast sequences achieved higher resolution than FLAIR and so calculations were based on these sequences. For 2D analysis of tumor burden, a measurement in millimeters was taken of the maximal tumor diameter on a single axial FLAIR (or axial T1 post-contrast section if applicable). The product of the two diameters was calculated to form the tumor bi-dimensional measurement [14, 18] , with the same sequence for each patient being used for MVS. The decision if to use the T1 post-contrast sequences was based on the opinion of the radiologist, depending on whether the enhancing component was judged to represent the entire tumor burden.
MVS was undertaken by two pediatric neuroradiologists for all lesions (FD'A, FD). The tumor outline was delineated on axial images manually for each MR image showing the lesion. The volume was then calculated using the Bregion of interest (ROI) volume calculate^plugin of the Osirix DICOM viewer (Osirix MD v.7.0.3, FDA cleared K101342, Pixmeo SARL, Switzerland), with intergap correction for FLAIR images [15] (Fig. 1 ). Table 1 shows response criteria for both 2D and volumetric assessments as described in the literature [18] . Minor response is quoted as a 25-49% decrease in the product of the perpendicular diameters on 2D measurements. For volumetric response criteria, progressive disease was defined as ≥ 40% increasing in calculated volume [18, 19] . This assumption of spherical volume presumes equal growth of tumor in each direction. Because RANO has extrapolated dimensions on the basis of a spherical shape of tumor, we further extrapolated this formula to include volumetric dimensions to facilitate comparison between the two methods. Other geometric models for tumor volume include the ellipsoid, cylinder, and rectangular formulas. The ellipsoid model defines volume as 1/6 π LWH, where L, W, and H represent diameters in the three axes of the tumor (length, width, and height) [20] , while the rectangular formula defines the product of LWH. The formula for the cylinder model is
assess that the ellipsoid geometric model most closely approximates tumor volume; however, both spherical and ellipsoid calculations showed significant variance in this comparison and correlations were poor, R = 0.62 and 0.531 for ellipsoid and spherical models, respectively [21] . A volumetric minor response criteria can be extrapolated from orthogonal diameter measurement using the formula from V = 4/3πr3 to include tumors with a 35-64% decrease in volume. We have therefore further sub-categorized patients to include minor response. It is important to note that the cut-off values for volumetric assessment represent a mathematical extrapolation from the linear values; in fact there are no prospective clinical studies available suggesting specific values for therapy response using volumetrics in pediatric brain tumors [18] .
All baseline and follow-up MRI studies were reviewed by a certified pediatric neuroradiologist (SL) to determine, if the volumetric assessment was consistent with the subjective interpretation of the changes in tumor size. The inter-reader variability in volumetric assessment was calculated on a sample of 12 baseline scans from the same study cohort using intraclass correlation coefficient (ICC).
Results
Patient characteristics
A total of 70 patients, aged 0.56 to 16.75 years with a diagnosis of pLGGs were included in the study. Thirty-seven patients were male. Fifty-five patients had a histologically proven diagnosis of pLGGs. Fifteen patients did not undergo biopsy; however, 14 of these had radiological appearances of an Fig. 1 Examples of ROI delineation for volume calculation on FLAIR axial images (a) and linear 2D measurements on the same slice (b). 3D volume rendering of the tumor has been obtained using Osirix compute volume plugin with intergap correction (c) and shows the irregular structure of the tumor which makes inadequate the assessment using linear measurements only optic pathway glioma (OPG), of whom 9 had a history of NF1. One further patient with NF1 and a hypothalamic tumor did not undergo biopsy. Thirteen of the 70 patients had a preexisting diagnosis of NF1. Patient demographics are listed in Table 2 .
Response assessments
The results in terms of difference in tumor size (%) between time zero and end-of-therapy follow-up are summarized in Table 3 . The median interval between studies is 522 days. On average, it took 10-15 min to complete MVS per patient/per scan. This did not include the time taken to export data and only included ROI drawing and software calculation of volume. ROI drawing time ranged between 5.5-10 min and 7.3 to 14.9 min for reader 1 (FD'A) and reader 2 (FD), respectively. Time taken to reach consensus on superior sequences for defining margins of the tumor is not included.
Fourteen (20%) of the 70 patients showed discordant results between 2D and MVS. Of these, 6 patients had SD on MVS with 2D assessment categorizing the response as PD. Five patients had SD on MVS with partial response (PR) identified on 2D assessment. Two patients had PD on MVS, but SD was observed on 2D assessment. One patient had PR on MVS, but SD reported on 2D assessment. Of the six patients who had SD on volumetric analysis, but PD on 2D assessment, two were pLGGs NOS, and two were pilocytic OPGs. The other two patients had tumors located in the thalamus and posterior fossa. Of the five patients with SD on MVS and PR on 2D, four patients had a diagnosis of OPG. Eight of the 14 discordant patients had OPG, i.e., 22% of all OPG patients studied.
In 56 of 70 patients, the volumetric and 2D tumor assessments were deemed to be concordant in terms of the response assessment. Of these 56, 5 were concordant but with more than 50% difference in the measurement of disease response observed between the two methods. All of these five patients had PD, and for these patients the volumetric measurements showed a greater degree of progression compared to the bidimensional measurement. Of the remaining 51 patients with concordant measurements by both methods, 39 had SD, 7 patients had PD, and 5 patients had PR.
When minor response (MR) is integrated to the analysis, three of the discordant patients with SD on MVS and PR in 2D assessment become MR in volumetric assessment. One discordant patient with PR on MVS and SD on 2D assessment became MR in 2D. Furthermore, when integrating MR into the analysis of the previously 56 concordant patients, 6 patients change from SD to MR in both MVS and 2D assessment. A further 4 patients remain in SD on MVS but move to MR in 2D assessment. Three patients move to MR on MVS but remain in SD on 2D assessment. Integrating MR brings the total discordant patient total to 21 (30%) of patient cohort.
There was a very good inter-reader variability for MSVon a sample of 12 patients (ICC = 0.9, supplementary table).
Discussion
Accurate response assessment is critical to determine the impact of therapies. This is the largest study in children with pLGGs performing a direct comparison of bi-dimensional and volumetric tumor measurements. In our cohort, 20% of patients had discordant response assessments between the two methods. For these patients the therapeutic response classification may change by performing a volumetric tumor assessment (allowing for the mathematical extrapolation of the cutoff values). This becomes significant when considering that radiological response is used as a primary endpoint in many pLGGs trials. Glioma measurements can be challenging due to lack of a distinct tumor border, irregular lesion shape, variation in acquisition technique, and head placement in the scanner [22, 23] . For pLGGs, the assessment of tumor burden according to the RANO criteria can be complicated by lack of gadolinium enhancement. Even in those pLGGs, in which contrast uptake is present, the enhancement pattern is often patchy and variable over time. In the majority of our patients, poorly enhancing neoplasms were present, which is significantly different from the adult glioblastomas (GBM) patient Percentage changes are measured from baseline. Product of perpendicular diameter in 2D assessment is measured on the section with the largest tumor area CR complete response, PR partial response, SD stable disease, PD, progressive disease group in whom the bi-dimensional measurement criteria were devised [6] . The Macdonald criteria defined Bsize^as the largest crosssectional area of the enhancing tumor [5] , which is not a description suitable for most pLGGs. RANO criteria further built on this definition by including the evaluation of T2/FLAIR WI, in addition to clinical symptoms and the use of corticosteroids, but they are again based on different neoplasms and age group [6] . On imaging, pLGGs often do not exhibit surrounding edema and are best visualized on FLAIR and T2WI MRI sequences [12] . In view of the variability in contrast uptake and possible underestimation of the tumor size, 72% of children in this study underwent assessment of tumor burden using FLAIR images. Furthermore, pLGGs differ considerably from adult counterpart in terms of molecular landscape and malignant transformation rate, which rarely occurs in the pediatric population [24, 25] .
For both RANO and Macdonald analyses, the radiologist decides the slice that should correspond to the largest appearing cross-section image of the tumor; this approach can be problematic for lesions that are non-spherical because structural heterogeneity and irregular borders can make it difficult to decide on the representative slice. In addition, slight variations on serial imaging (e.g., with a slightly different image plane, head placement) might impact reproducibility of measurements in irregular lesions [4, 23, 26] . In GBM, a good correlation between volumetric and bi-dimensional measurements was found [13] ; this may be due, at least in part, to the fact that GBM grow very rapidly [27] , and therefore, small measuring errors would still produce the same result in terms of response criteria.
The subjective visual analysis of the tumor response was consistent with the volumetric measurements in all cases, including in those cases, in which the radiological reports were discordant with 2D measurements. This was probably due to the irregular shape of the tumors, which may have limited the 2D assessment accuracy based on one slice only (Fig. 2) . While one may argue that the volumetric assessment is only as good as judgment of a trained radiologist, clinical trials require the objectively reproducible data for analysis, and therefore, a consistent method of assessment of tumor size is necessary.
The manual segmentation method used in our study is not significantly time consuming therefore encouraging its integration into the clinical workflow. Additionally, this method has shown excellent inter-rater reproducibility in a test sample of 12 patients.
Most automatic and semi-automatic algorithms to date have only reliably been shown to work in gadolinium enhancing lesions such as GBM [14] . In a study by Akkus et al. of semi-automated segmentation of pLGGs on MRI T1 postcontrast and T2 WI, the intra-operator variability was lower than intra-expert variability and inter-operator variability much smaller than inter-expert variability [28] . While this is encouraging for establishing a standardized method of semiautomated analysis tumor volume in future, such methods need specific software, time for the operator to check the segmentation results and may be more useful for very complex and extensive lesions such as plexiform neurofibromas than relatively small pLGG [29] . In a further study by Porz et al., semi-automated analysis of tumor volume was shown to be comparable to a full automated method of assessment [30] ; Patients who had discordant results of the tumor response assessment are in italic SD stable disease, PD progressive disease, PR partial response, MR minor response Fig. 2 The tumor in the slice 1 (used for 2D assessment) is stable in baseline and follow-up scans; however, on follow-up, the mass appears to be less bulky in upper slices (slice 2). The volumetric assessment confirmed the reduction in size (i.e., partial response) that was not appreciable using linear measurement on slice 1 however, in this study, all tumors were high-grade enhancing masses. The lack or heterogeneity of enhancement typical of pLGGs and their relatively limited extension would likely hamper such an automated volumetric assessment and favor manual volumetric methods. In our cohort, 20% of patients had discordant response assessments between the two methods. For these patients the therapeutic response classification may change by performing a volumetric tumor assessment (allowing for the mathematical extrapolation of the cut-off values). This becomes significant when considering that radiological response is used as a primary endpoint in many pLGGs trials. In the context of OPGs, this may be of particular interest in view of the need to detect early tumor progression for patients whose functional vision is at risk. We would suggest volumetric assessment in pLGGs may be also valuable in clinical practice where a discrepancy exists between 2D assessment and the subjective analysis by the expert radiologist. The relatively short time taken for the volumetric assessment using our method makes this strategy useful for clinical practice.
Study limitations
There are number of limiting factors of this study. One possible drawback is the need of specific software and correspondent expertise required to undertake volumetric assessment. This has been noted as a limiting factor in previous studies [14] , even though our method is relatively simple to use in comparison with semi-automatic volumetric assessment.
Another aspect to be considered is the fact that for some patients, we used FLAIR images, while for others, we used post-contrast 3D T1 images. Although this makes the method not entirely consistent, when evaluating subjectively a mass, a radiologist in clinical practice critically uses the sequence where the lesion is better visualized, so it seems reasonable, in our opinion, to assess the volume using the same process. The lack of clinical data is noted to be a limiting factor of the study. The focus of this study, however, is to compare the methods of 2D and MVS assessment of tumor burden. The cohort of patients is part of a larger cohort of pLGG patients, whose assessment of response has not used volumetric data prospectively.
A further limiting factor is the slice thickness/gap (particularly relevant in FLAIR images); however, the same limitations would influence the linear measurements and the software corrects for slice thickness/gap, with reduction of possible inaccuracies. Our method seems to be a good compromise between time and accuracy of measurement in the context of non-enhancing tumors since, at the moment, the use of automatic segmentation is not reliable [31] . Finally, as explained in the BData analysis^section, to use cut-off for volumetrics response based on a spherical mathematical extrapolation of linear measurements is suboptimal; however, there are no prospective studies establishing cut-off values for LGG and this limiting factor stressed the advantage of using volumetric direct measurements.
Conclusion
Assessment according to RANO criteria is not reliable for complex-shaped lesions such as pLGG; manual volumetric segmentation using the Osirix software appears to be a feasible and more accurate method to quantify changes in tumor bulk on serial imaging. Furthermore, in a significant proportion of our patients with pLGGs, volumetric segmentation results may differ substantially from bi-dimensional measurements, and may have a clinical impact in management of the patients and in evaluation of tumor response in clinical trials.
